Trials / Completed
CompletedNCT00444340
An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis
An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enbrel (Etanercept) |
Timeline
- Start date
- 2004-04-01
- Completion
- 2007-07-01
- First posted
- 2007-03-07
- Last updated
- 2007-12-07
Source: ClinicalTrials.gov record NCT00444340. Inclusion in this directory is not an endorsement.